Adolor Corporation to Present at the UBS Global Life Sciences Conference

• Press Release
• Source: Adolor Corporation
• On 4:28 pm EDT, Monday September 21, 2009

EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (NasdaqGM:ADLR - News) today announced that management will present at the UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 4:00 P.M. Eastern Time. The conference is being held at the Grand Hyatt, New York, New York.

Related Quotes

Symbol	Price	Change
ADLR	1.49	-0.01

{"s" : "adlr","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Adolor’s presentation will be webcast live for investors through www.adolor.com and available for a period of one week following the conference.

About Adolor Corporation

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Adolor’s first approved product in the United States is ENTEREG® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the E.A.S.E.™ Program. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com. In collaboration with GlaxoSmithKline (GSK), the Company launched ENTEREG in mid-2008.

The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a peripheral mu opioid receptor antagonist entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.

For more information, visit www.adolor.com.

Adolor Corporation
Lizanne Wentz, 484-595-1500